Proteomic and metallomic strategies for understanding the mode of action of anticancer metallodrugs. by Gabbiani, Chiara et al.
324 Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 324-337 
        1871-5206/10 $55.00+.00 © 2010 Bentham Science Publishers Ltd. 
Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anti-
cancer Metallodrugs 
Chiara Gabbiania, Francesca Magherinib, Alessandra Modestib and Luigi Messoria,* 
a
Department of Chemistry, University of Florence, via della Lastruccia, 3, 50019 Sesto Fiorentino, Florence, Italy; 
b
Department of 
Biochemical Sciences, University of Florence, Viale G. Morgagni, 50, 50134 Florence, Italy 
Abstract: Since the discovery of cisplatin and its introduction in the clinics, metal compounds have been intensely investigated in view 
of their possible application in cancer therapy. In this frame, a deeper understanding of their mode of action, still rather obscure, might 
turn crucial for the design and the obtainment of new and better anticancer agents. Due to the extreme complexity of the biological sys-
tems, it is now widely accepted that innovative and information-rich methods are absolutely needed to afford such a goal. Recently, both 
proteomic and metallomic strategies were successfully implemented for the elucidation of specific mechanistic features of anticancer 
metallodrugs within an innovative “Systems Biology” perspective. Particular attention was paid to the following issues: i) proteomic 
studies of the molecular basis of platinum resistance; ii) proteomic analysis of cellular responses to cytotoxic metallodrugs; iii) metal-
lomic studies of the transformation and fate of metallodrugs in cellular systems. Notably, those pioneering studies, that are reviewed 
here, allowed a significant progress in the understanding of the molecular mechanisms of metal based drugs at the cellular level. A fur-
ther extension of those studies and a closer integration of proteomic and metallomic strategies and technologies might realistically lead to 
rapid and significant advancements in the mechanistic knowledge of anticancer metallodrugs.  
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1. ANTICANCER METALLODRUGS: SOME INTRODUC-
TORY REMARKS 
 Metal-based chemotherapy is nowadays a well established 
therapeutic option for cancer treatment [1]. Remarkably, cisplatin, 
carboplatin and oxaliplatin, three strictly related inorganic plati-
num(II) complexes (Fig. 1), are among the most widely used anti-
cancer drugs worldwide [2]. They proved to be very effective in the 
treatment of a variety of cancers, especially testicular cancer (for 
which cisplatin has a >90% cure rate), ovarian cancer, head and 
neck cancers and, also, for colorectal cancer (specifically respond-
ing to oxaliplatin); moreover, classical platinum drugs are now part 
of several established chemotherapeutic protocols for cancer treat-
ment.  
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Chemical formulas of classical platinum compounds. 
 Anticancer platinum(II) complexes are believed to exert their 
relevant biological effects primarily by interacting with double 
helix DNA, causing irreversible DNA damage and thus inducing 
apoptotic death of the cancer cell [2]. The mechanism of action of 
platinum compounds, on which there is now a rather large consen-
sus, is summarised in Fig. (2); it basically relies on bidentate plati-
num(II) coordination to two adjacent DNA purine nucleobases 
leading to a relevant local distortion of the DNA double helix. This  
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is the clue event capable of triggering a complex cascade of down 
stream biochemical processes, ultimately ending with cancer cell 
apoptosis. 
 Unfortunately, similar to most established anticancer drugs, 
cisplatin and its analogues manifest a rather poor selectivity toward 
cancer cells and may also attack several other types of rapidly di-
viding healthy cells [3]. Therefore, nearly all patients treated with 
platinum drugs commonly experience severe side effects often lead-
ing to treatment suspension. The issue of drug resistance (i.e. plati-
num resistance) is another important limitation for platinum drugs; 
indeed, platinum chemotherapy often induces acquired tumor resis-
tance, in most cases causing treatment failure. Accordingly, the 
molecular mechanisms of platinum drugs leading either to systemic 
toxicity or to acquired platinum resistance have been the subject of 
intense investigations; it is believed that a full understanding of 
those biochemical processes might greatly help in counteracting 
and overcoming these phenomena, thus resulting into important 
clinical progresses.  
 Owing to the relevant drawbacks of classical platinum(II) 
drugs, several additional platinum and non-platinum metal-based 
compounds were designed, prepared, and tested during the last 
three decades with the goal of identifying compounds that might 
lack the undesirable activities of cisplatin, particularly host toxicity, 
and manifest a different spectrum of anticancer actions.  
 Some significant success was obtained with a variety of uncon-
ventional platinum drugs. For instance, a few polynuclear platinum 
complexes, developed by Farrell et al., manifested outstanding 
antiproliferative effects in vitro and favourable antitumor effects in 
vivo [4]; pairwise some trans platinum(II) compounds, developed 
by various research groups worldwide, showed very promising 
pharmacological profiles [5-7]. Platinum(IV) compounds were also 
shown to behave as useful precursors for platinum(II) drugs with a 
generally lower systemic toxicity than platinum(II) congeners; in-
deed, upon reduction within the reducing milieu of cancer cells, 
they may be converted into biologically active platinum(II) species 
[8].  
 In addition, other classes of metal compounds (non platinum 
metallodrugs) were developed and intensely investigated in the 
search of new anticancer leads (e.g. ruthenium, titanium, tin, gold, 
copper, etc.). Some of them displayed a promising pharmacological 
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profile and peculiar biological features that are profoundly different 
from those of classical platinum compounds. 
 Ruthenium compounds, in particular, were the object of much 
interest. Among them, NAMI A, KP1019 and a few novel ruthe-
nium arene compounds manifested, on the whole, very attractive 
pharmacological properties, both in vitro and in vivo. Remarkably, 
NAMI A, while being poorly cytotoxic, displayed excellent antime-
tastatic properties and, for this reason, is currently undergoing 
phase II clinical trials [9, 10]. 
 Gold compounds constitute another class of promising cyto-
toxic and anticancer metallodrugs. Several gold compounds, both 
gold(I) and gold(III), showed favourable antiproliferative properties 
in vitro against a variety of human tumor cell lines. For some of 
them excellent results in vivo were obtained as well. In particular, 
gold(III) dithiocarbamates [11-13] and gold(III) porphyrins [14, 15] 
form two classes of promising agents for further pharmacological 
development and are currently undergoing advanced preclinical 
testing [16].  
 In the course of the numerous investigations on anticancer  
metallodrugs, much interest has focused on the elucidation of the 
likely molecular mechanisms in the belief that a precise knowledge 
of their mode of action might better direct the design and the syn-
thesis of novel anticancer metallodrugs. Indeed, the “true” molecu-
lar mechanisms of anticancer metallodrugs are still largely un-
known as well as the involved biochemical pathways leading to 
resistance and toxicity. The understanding of those mechanisms 
might bring to a significant progress in this research area and allow 
the obtainment of more effective anticancer metallodrugs. At the 
same time, it is now evident that understanding to a satisfactory 
degree the mode of action of a drug at the molecular level requires 
gathering a great amount of experimental data on drug/biomole-
cules interactions and deciphering and interpreting, at least par-
tially, the huge complexity that is intrinsic to biological systems, as 
it will be discussed below.  
2. COPING WITH THE INHERENT COMPLEXITY OF 
BIOLOGICAL SYSTEMS: “SYSTEMS BIOLOGY” AND THE 
“OMICS” SCIENCES 
 Biological systems are characterised by a very high degree of 
internal complexity. Even “simple” isolated cells are the result of 
the complex interplay of thousands of genes, proteins and small 
molecules according to well defined -but yet not completely  
understood- principles of structural and functional organisation. 
Following the dramatic increase in the biological knowledge that 
has taken place during the last two decades, this concept, “the in-
herent complexity of biological systems”, has reached its maturity 
and is widely accepted within the scientific community. Thus, new 
disciplines and new methods are now absolutely needed to tackle 
with the huge complexity of biological systems and try to interpret 
it. These new disciplines and methods may turn crucial to under-
stand in more depth the mode of action of biologically active sub-
stances at the molecular level.  
 In this frame, Systems biology is a term now largely employed 
to describe current trends in bioscience research [17-19]. Systems 
biology may be defined as an inter-disciplinary study field which is 
mainly devoted to the analysis of the complex interactions that 
occur within biological systems. Basically, those interactions are 
investigated with the aid of new experimental methods according to 
an innovative conceptual perspective (holism instead of 
reductionism). In other words, systems biology is the study of an 
organism, considered as an integrated and interacting network of 
genes, proteins and biochemical processes that give rise to life. 
Instead of studying individual components or aspects of a certain 
organism, systems biologists rather focus on all its components and 
on their mutual interactions, each considered as a part of one single 
system. According to this new perspective, the action of a drug is 
no more interpreted in terms of the simple interaction of the drug 
with its primary target but, rather, on the basis of the numerous 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The mechanism of action of platinum compounds. 
 
 
 
 
 
 
 
 
Fig. (3). Schematic drawings of some representative ruthenium compounds. 
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interactions that the drug itself establishes with a large variety of 
biomolecules. These several interactions will determine not only 
drug’s activity but also its toxicity, bioavailability, biodistribution, 
metabolism and so on, in other words its overall pharmacological 
profile.  
 Thus, Systems Biology mainly refers to the ability to obtain, 
integrate and analyze complex sets of data from multiple experi-
mental sources using interdisciplinary tools. Omics sciences such as 
Genomics, Epigenetics, Transcriptomics, Interferomics, 
Proteomics, Metabolomic, etc, represent the typical technological 
platforms for systems biology. As these disciplines have the poten-
tial to produce huge amounts of new experimental data, a major 
goal for systems biologists will be to develop smart and robust 
methods, to mine, analyse and interpret such data. Bioinformatics is 
the discipline specifically deputed to this goal [20-23]. 
 The bioinformatic analysis often involves the development of 
mechanistic models, such as the reconstruction of dynamic systems 
starting from the quantitative properties of their elementary build-
ing blocks [24, 25]. For example, a cellular network can be mod-
elled using methods derived from chemical kinetics and from con-
trol theory. Due to the great number of parameters, variables and 
constraints, that are typically present in a cellular network, ad-
vanced numerical and computational techniques are often employed 
for bioinformatic analysis. 
 In recent years Bioinformatics has been extensively applied to 
systems biology and to the interpretation of proteomic data [26, 27]. 
The main goal of these studies consists in referring the observed 
alterations of the proteomic profiles –recorded under well defined 
experimental conditions- to specific modifications in selected meta-
bolic or signalling pathways. This type of analysis requires exten-
sive identification and functional annotation of proteins.  
 Owing to the intrinsic complexity of biological systems it is 
evident that determining the exact mode of action of a drug repre-
sents today a formidable and very ambitious task. Moreover, as 
most metallodrugs are prodrugs, characterised by a high propensity 
to react with very many biomolecules and to give rise to several 
active metabolites, a full understading of their mechanism of action 
turns out to be a goal even more difficult and more ambitious than 
in the case of classical organic drugs. 
 Within this frame the Omics sciences offer valuable tools to 
gain mechanistic information on metallodrugs. Indeed, large collec-
tions of data can be straightforwardly obtained from their applica-
tion that, need, afterward, to be analysed and organised systemati-
cally. The interpretative efforts based on novel bioinformatics tools 
have the potential to refer the observed alterations to specific modi-
fications of metabolic and signalling pathways of the cell. This kind 
of analysis may be extremely valuable in the process of target dis-
covery as nicely illustrated in a recent paper [28]. 
 The focus of our review article will be on both Proteomics and 
Metallomics. While Proteomics is now an established branch of the 
new omics sciences, Metallomics is a younger discipline still in the 
search of a definitive conceptual and methodological organisation 
as it will be discussed below in more detail. In particular, we will 
report here on the exploitation of novel proteomic and metallomic 
methodologies to gain insight into the mode of action, and also the 
mechanisms of toxicity and resistance, of a few representative anti-
cancer metallodrugs. An interesting review on the application of 
proteomics methods to investigate the mechanism of anticancer 
metallodrugs has appeared a couple of years ago [29]. Moreover, a 
very comprehensive review on the studies concerning the interac-
tions of metallodrugs with serum proteins has appeared somehow 
earlier [30]. 
3. PROTEOMICS: GENERAL REMARKS 
 Proteomics is the “large-scale study of proteins”, with a par-
ticular emphasis on their structures and functions [31, 32]. Proteins 
form a crucial part of the living organisms, as they are the main 
components of the metabolic and signalling pathways of cells while 
playing, concomitantly, very important structural roles. The term 
proteomics was first introduced in 1997 [33] in analogy with 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). (A) Established gold(I) compounds in clinical use: solganol (a), allocrysin (b), myocrysin (c), sanocrysin (d) and auranofin (e). (B) Some representa-
tive gold(III) compounds: [Au(terpy)Cl]Cl2 (1), [Au(bipy
c-H)(OH)][PF6] (2), the dinuclear AuOXO6 complex (3), gold (III) meso-tetraarylporphyrins com-
plexes(4) and the gold(III) dithiocarbamate complexes containing N,N-dimethyldithiocarbamate (5) and ethylsarcosinedithiocarbamate (6) ligands.  
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genomics, the “study of the genes”. In turn, the word "proteome", 
coined by Marc Wilkins in 1994, is a blend of "protein" and "ge-
nome". It defines the entire complement of proteins [34], produced 
by an organism or system. Thus, the proteome may greatly vary 
with time in dependence of the requirements, or stresses, to which a 
cell or organism may be exposed and these alterations may be the 
object of specific investigation.  
 The proteomic technology, is aimed to separate, identify, and 
characterize a global set of proteins in such a way to provide infor-
mation on protein abundance, location, modification, and protein-
protein interaction in the proteome of a given biological system. 
This technology offers a direct measurement of the presence and of 
the relative abundance of proteins, and reveals the consequence of 
protein functioning and networking in determining the biological 
phenotype of organisms under various conditions. By studying 
changes in protein expression, in health and disease or upon drug 
treatment, proteomics may provide important insights into the mo-
lecular basis of disease, may help in the validation of drug targets, 
and may offer accurate descriptions of drug action, toxicity, and 
side effects. 
 In the field of proteomics, several well-established methods are 
now available to resolve and analyze complex mixtures of proteins 
derived from cells and tissues. Currently, the most commonly used 
proteomic platform includes a method for proteins separation, such 
as two-dimensional gel electrophoresis (2D-GE) or Liquid chroma-
tography (LC) (Table 1), most often coupled with a variety of mass 
spectrometry methods (matrix-assisted laser desorption/ionization 
time of flight (MALDI-TOF) [35], electrospray ionization mass 
spectrometry (ESI-MS) [36], and/or tandem mass spectrometry 
(MS/MS). In addition, inductively coupled plasma (ICP) mass spec-
trometry and surface enhanced laser desorption ionization time of 
flight (SELDI-TOF) [37] were also applied with success in the 
proteomic research.  
 In general, several different technological platforms can be used 
in proteomic studies and each technique has its own advantages and 
limitations (see Table 1). 
 Protein separation with two dimensional electrophoresis (2D-
GE), still the standard approach, involves initial separation of pro-
teins based on their isoelectric point followed by subsequent separa-
tion based on size. This strategy is a robust method that separates 
intact proteins, and allows evidencing the presence of isoforms and 
post-translational modifications as well as determining their respec-
tive expression levels. Unfortunately, this method is not applicable 
to polypeptides smaller than 10 kDa; in addition, 2D-GE usually 
shows severe problems in the separation of highly hydrophobic 
proteins and is time consuming. The introduction of Differential In 
Gel Electrophoresis (DIGE) by the group of Jonathan Minden in 
1997 [38] has been one of the major hallmarks in the application of 
2D electrophoresis method to proteomics in the last years. This 
method is based on the fluorescently tagging of proteins in different 
samples with different dyes and allows a more rapid and sensitive 
comparison of samples. In combination with MALDI-TOF MS, 
2D-GE constitutes the standard method in expression proteomics.  
 Hydrophobic membrane proteins are hardly detectable after 2D-
GE. Therefore, any global and comprehensive analysis of the mem-
brane proteomes has not been reported yet. Blue native poly-
acryamide gel electrophoresis represents an alternative strategy to 
separating membrane proteins with high resolution while conserv-
ing their enzymatic function. The method is powerful between 10 
and 10 000 kDa. Also, membrane protein complexes are separated 
well after solubilization of complexes with mild neutral detergents. 
The separation principle relies on binding of Coomassie blue G250 
which provides negative charges to the surface of the protein [39]. 
 In an alternative approach, called shotgun proteomics, [40] 
proteins are digested and peptides are then separated by liquid-
based separation in one or several dimensions prior to detection by 
tandem mass spectrometry (MS/MS). This is a fast method that 
requires little sample handling and manual work. The peptide 
masses are then interpreted using bioinformatic tools. This is a 
critical point in shotgun proteomics, where reliable statistical meth-
ods are needed in order to distinguish true protein hits from false 
positives. One limit of shotgun approaches is that information on 
the intact proteins and isoforms is lost during the digestion step. 
Recently, a big effort was made in order to develop “gel-free” 
quantitative methods. Briefly, these approaches can be divided into 
two main families: “stable isotope based” such as SILAC (stable 
isotope labelling in cell culture), GIST (global internal standard 
technology), iTRAQ,(isotope tags relative and absolute quantifica-
tion),or ICAT (isotope coded affinity tag) and “label-free meth-
ods”. The first kind of approach uses stable isotopes to label pep-
tides, introducing a mass difference between the labeled and unla-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Graphical presentation of some relevant signal transduction pathways. 
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Fig. (6). (A) Schematic overview of current approaches for mass spectrometry-based proteomic studies. Proteins are extracted from biological sample, sepa-
rated by 2DGE or LC and identified by MS. (B) In SELDI-MS approach the sample is deposited on the active chip surface. After several washing steps, only a 
few proteins stay bound to the surface; these are subsequently analyzed using low-resolution MS. 
Table 1. A Summary of the Main Advantages and Limitations of Different Proteomic Methodologies 
 Advantages Limitations 
2DGE 2-DE Available in most proteomics labs, simple to perform, quantitative, 
low cost. 
Time-consuming, no automation, not applicable for pro-
teins/polypeptides with molecular masses < 10 kDa, limited use for 
hydrophobic proteins. 
LC-MS Automation, multidimensional, high sensitivity. Quantitative analysis is not simple, sensitive toward interfering com-
pounds, digestion destroy information on isoforms, high cost. 
ICAT Quantitative. Only cysteine residues are labelled, digestion destroy information on 
isoforms, high cost. 
SILAC Quantitative, all proteins are labeled. Digestion destroys information on isoforms. 
SELDI-TOF MS 
Restricted to selected 
proteins,  
Easy-to-use system, high-throughput, automation, low sample volume 
required. 
low-resolution MS, low information content, reproducibility is still 
problematic. 
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beled peptides in the process. The intensity signals obtained from 
the unlabeled and labeled peptide will then provide quantitative 
information in the MS spectrum [for review see 41,42]. The second 
family of methods does not introduce any label, and usually relies 
on chromatographic and mass spectrometry data to quantify pep-
tides in the samples. This last method is not easy to perform, re-
quires high resolution of peptides and an accurate process for data 
normalization.  
 In the last decade we also assisted to an increasing utilization of 
SELDI-MS technology in clinical proteomics. The process involves 
binding of the sample to a Protein Chip array which is subsequently 
washed several times to remove unbound proteins and buffers. The 
Protein Chip is then directly subjected to mass spectrometry by 
MALDI-TOF. The mass-to-charge ratios for desorbed molecules 
are analysed as they fly down the TOF tube and an individual pro-
tein spectrum is generated for each sample tested. Differentially 
expressed proteins are determined from the protein profiles by 
comparing the peak intensities of spectra [for review see 43].  
 While the analysis of large biopolymers is successfully per-
formed by electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI), analysis of low molecular weight 
molecules such as amino acids, pharmaceuticals, hormones, etc. is 
predominantly performed by ESI mass spectrometry with quad-
rupole mass analyzers. The major reasons for not using MALDI are 
the abundance of matrix ions in the low mass region and the lack of 
reasonable precursor selection in a MALDI tandem instrument. 
Also, until recently, MALDI was not considered to be a technique 
capable of providing robust quantitative data. 
 However, a new matrix-assisted laser desorption/ionization 
(MALDI) time-of-flight/time-of-flight (TOF/TOF) high-resolution 
tandem mass spectrometer technique is now available that com-
bines the advantages of high sensitivity for peptide analysis associ-
ated with MALDI and comprehensive fragmentation information 
provided by high-energy collision-induced dissociation (CID) [44]. 
 Proteomics thus holds great promise as a powerful technique 
for analysing in detail drug induced proteomic changes and to iden-
tify pathways and protein targets that are specifically affected by a 
certain substance. It must be reminded, however, that numerous 
drug-targeted proteins are membrane-bound proteins, for example, 
receptors and ion channels. These proteins may not be suitable for 
classical proteomic investigations due to their poor solubility and 
low abundance, and accordingly may be severely underrepresented 
or even completely lost in the proteome profiles. 
4. PROTEOMIC STUDIES OF ANTICANCER METALLO-
DRUGS 
 During the last few years a number of studies have appeared 
where classical proteomics methodology was applied to the mecha-
nistic investigation of anticancer metallodrugs. Roughly, those stud-
ies may be referred to two main applications.  
 The first type of application deals with the elucidation of the 
molecular basis of resistance to platinum drugs. Resistance to 
platinum most likely relies on the overexpression of specific pro-
teins, endowed with a variety of functions that make the cell far less 
sensitive to the insult caused by the platinum compounds. The ra-
tionale for these studies is thus rather straightforward: the proteo-
mes of platinum sensitive cancer cell lines and of their platinum 
resistant counterparts are comparatively assayed in order to high-
light differentially expressed proteins among which are most likely 
those responsible for platinum resistance.  
 The second type of application concerns the analysis of proteo-
mic alterations induced by cells exposure to a cytotoxic metallo-
drug. Experimentally, the proteomic profiles of cancer cell lines 
treated with a specific metallodrug are analysed in comparison to 
those of untreated cells, and differentially expressed proteins are 
highlighted and identified. This type of analysis, in principle, may 
allow identification of proteins belonging to the main affected bio-
chemical pathways that are strictly related to early events of cell 
damage and to the molecular mechanisms of stress response. When 
the insult is too severe and cannot be repaired the apoptotic process 
is started and the corresponding proteomic signatures may be de-
tected.  
a) Analysis of the Molecular Basis of Platinum Resistance 
Through Comparative Proteomic Analysis of Pt Sensitive vs Pt 
Resistant Cell Lines 
 The studies on the molecular basis of drug resistance are abun-
dant in the field of platinum drugs. Indeed, acquired resistance is 
often the reason for treatment failure and attracts therefore great 
interest. Understanding the molecular mechanism of resistance 
might hopefully lead to new methods to circumvent it. Thus, a con-
spicuous number of Proteomic studies were specifically devoted to 
this issue. 
 An interesting study on platinum resistance was reported a few 
years ago by Castagna et al. [45]. In this paper, cisplatin resistance 
and drug response in human tumor cervix squamous carcinoma cell 
lines A431 were investigated. The experimental set-up involved not 
just a two-way comparison of the control vs. the drug-resistant cell 
line, but also an acute cisplatin treatment of both cell lines, leading 
to a four-way comparison. An appreciable modulation of protein 
expression was thus revealed, that could be classified under various 
functional classes, such as molecular chaperones (e.g. heat-shock 
proteins HSP60, HSP90, HSC71, heat-shock cognate 71 kDa pro-
tein), calcium binding proteins (e.g. calmodulin, calumenin), pro-
teins involved in drug detoxification and redox metabolism (such as 
peroxiredoxins PRX 2 and PRX 6, and glutathione-S-transferase, 
GST), anti-apoptotic proteins (such as 14-3-3 switched on in cis-
platin-exposed cells) and ion channels (such as VDAC-1, voltage-
dependent anion-selective channel). 
  In particular, the basal levels of HSC71 and HSP60 were 
greatly increased in A431/Pt cells compared to A431 cells. Moreo-
ver, cisplatin exposure up-regulated the anti-apoptotic 14-3-3 pro-
tein in both cell lines, GST in the sensitive cells and PRX6 in 
A431/Pt cells. These findings are consistent with a constitutive 
expression of defence factors by resistant cells and with activation 
by cisplatin of mechanisms capable of protecting cells from drug-
induced damage. This pattern of response, also observed in parental 
cells, could reflect an intrinsic resistance of this tumor type. 
 Another important study was communicated by Le Moguen  
et al. in 2006 [46].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Proteomic comparison between IGROV1 and IGROV1-R10 cells 
using 2-DE and MALDI-TOF-MS (from ref. 46).  
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 A classical proteomic approach was applied by these authors to 
identify proteins associated with platinum resistance in IGROV1 
ovarian carcinoma cells. First, the proteomic pattern of the cis-
platin-sensitive ovarian cell line IGROV1 was established using 
MALDI-TOF-MS and PMF. Then, the resulting 2-D pattern was 
compared with that of the cisplatin-resistant counterpart IGROV1-
R10. Among the 40 identified proteins, cytokeratins 8 and 18 and 
aldehyde dehydrogenase 1 were greatly overexpressed in IGROV1-
R10, whereas annexin IV was down-regulated. These observations 
were subsequently confirmed by Western blotting. 
 This kind of investigation was deepened and extended shortly 
after by the same research group [47]. A kinetic analysis of 
IGROV1 cells following treatment with cisplatin and subsequent 
statistical analysis revealed time and/or concentration-dependent 
modifications in protein expression. This study evidenced events 
such as a decreased amino-acid and nucleotide synthesis possibly 
associated with cell cycle blockade, and variations that might be 
related to resistance acquisition, such as enhanced glycolysis and 
increased proliferating potential. Overexpression of aldehyde dehy-
drogenase 1 and of both cytokeratins 8 and 18 were confirmed in 
consistency with the previous study. The expression of these pro-
teins was increased in cisplatin-resistant IGROV1-R10 compared to 
IGROV1 parental cells. Identification of such differentially ex-
pressed proteins could allow an improved understanding of the 
mechanisms leading to cell death or survival and, thus, to the acqui-
sition of chemoresistance. In a way, this study established some 
meaningful correlations between the cellular response to metallo-
drugs and the mechanisms of acquired resistance. 
 In turn, Pan et al. [48], established a few platinum-resistant 
human ovarian cancer cell lines and identified differentially ex-
pressed proteins related to platinum resistance. The total proteins of 
two sensitive (SKOV3 and A2780) and four resistant 
(SKOV3/CDDP, SKOV3/CBP, A2780/CDDP, and A2780/CBP) 
human ovarian cancer cell lines were isolated by two-dimensional 
gel electrophoresis (2-DE). The differentially expressed proteins 
were identified using MALDI-TOF MS. In total, 57 differential 
protein spots were detected. Five proteins, including annexin A3, 
destrin, cofilin 1, Glutathione-S-transferase omega 1 (GSTO1-1), 
and cytosolic NADP+-dependent isocitrate dehydrogenase (IDHc), 
were specifically affected compared with their parental platinum 
sensitive cells. The expression of the above mentioned five proteins 
was validated by quantitative PCR and Western blot; notably, the 
Western blot results showed nearly complete consistency with pro-
teomic results. The above five proteins are likely to be good candi-
dates for platinum resistance. These may be useful for further study 
of resistance mechanisms and for the screening of resistance bio-
markers. 
 A very comprehensive study was reported by Stewart JJ et al. 
[49]. Indeed, ICAT coupled with tandem MS is a quantitative pro-
teomic technique for high throughput protein expression profiling 
of complex protein mixtures. Using ICAT/MS/MS approach, the 
nuclear, cytosolic, and microsomal fractions obtained from 
IGROV-1 (cisplatin-sensitive) and IGROV-1/CP (cisplatin-
resistant) ovarian cancer cell lines were comparatively profiled. The 
proteomes of cisplatin-sensitive and -resistant ovarian cancer cells 
were compared , and protein expression was correlated with mRNA 
expression profiles. A total of 1117 proteins were identified and 
quantified. The relative expression of 121 of these varied signifi-
cantly between the two cell lines. Sixty-three proteins were overex-
pressed in cisplatin-sensitive, and 58 were over expressed in cis-
platin-resistant cells. Examples of proteins at least 5-fold overex-
pressed in resistant cells and with biological relevance to cancer 
include cell recognition molecule CASPR3 (13.3-fold), S100 pro-
tein family members (8.7-fold), junction adhesion molecule Claudin 
4 (7.2-fold), and CDC42-binding protein kinase beta (5.4-fold). 
Examples of cancer-related proteins at least 5-fold overexpressed in 
sensitive cells include hepatocyte growth factor inhibitor 1B (13.3-
fold) and programmed cell death 6-interacting protein (12.7-fold). 
The direction of changes in expression levels between proteins and 
mRNAs were not always the same, possibly reflecting posttran-
scriptional control of protein expression. Proteins whose expression 
profiles correlate with cisplatin resistance in ovarian cancer cells 
were identified. These proteins may be involved in modulating 
response to cisplatin and may have potential as markers of treat-
ment response or treatment targets. 
 A further proteomic study by Smith L et al. [50] analysed cis-
platin resistance in breast cancer cells. The MCF-7 breast cancer 
cell line and a novel derivative displaying significant resistance to 
cisplatin were analyzed using two-dimensional gel electrophoresis. 
The protein profiles were compared and 15 differentially expressed 
proteins identified by matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry. Downregulation of beta-tubulin 
type 3, cytokeratin 17, tropomyosin 1-alpha, peroxiredoxin 4, heat 
shock 27-kDa protein 1, glutathione-S-transferase mu 3, ribosomal 
protein P0, isocitrate dehydrogenase 3, and peptidyl-prolyl 
isomerase A isoform 1 was detected in cisplatin-resistant cells. In 
contrast, the expression of hydroxyprostaglandin dehydrogenase 
15-(NAD), matrix metalloproteinase 9, heterogeneous nuclear ribo-
nucleoprotein A3, proteasome beta 1 subunit, electron transfer fla-
voprotein beta-polypeptide isoform 1, and peptidyl-propyl 
isomerase B precursor was enhanced in cisplatin-resistant cells. The 
downregulation (at least twofold) of glutathione-S-transferase mu 3, 
cytokeratin 17, and peroxiredoxin 4 was confirmed by Western 
blotting.  
 Very recently Martinez-Balibrea E et al. [51] published an in-
teresting proteomic study on the molecular mechanisms involved in 
oxaliplatin resistance in colorectal cancer. A 5-fold oxaliplatin-
resistant cell line, HTOXAR3, was compared with its parental cell 
line, HT29, using two-dimensional PAGE. Mass spectrometry, 
Western blot, and real-time quantitative PCR confirmed the down-
regulation of pyruvate kinase M2 (PK-M2) in HTOXAR3 cells. In a 
panel of eight colorectal cancer cell lines, a negative correlation 
was found between oxaliplatin resistance and PK-M2 mRNA lev-
els. Oxaliplatin exposure in both HT29 and HTOXAR3 led to PK-
M2 mRNA up-regulation. PK-M2 mRNA levels were measured by 
real-time quantitative PCR in 41 tumors treated with oxaliplatin/5-
fluorouracil. Tumors with the lowest PK-M2 levels attained the 
lowest response rates (20% versus 64.5%). High PK-M2 levels 
were associated with high p53 levels. In conclusion, the data pre-
sented by these authors provided a clear link between PK-M2 ex-
pression and oxaliplatin resistance mechanisms and further impli-
cated PK-M2 as a predictive marker of response in patients with 
oxaliplatin-treated colorectal cancer. 
 Overall, the above mentioned studies, although not conclusive, 
have delineated some common investigative strategies and also 
highlighted some general trends in the platinum resistance mecha-
nisms. In several cases, a few specific proteins have emerged as a 
signature of platinum resistance being the likely candidates for 
sustaining the associated biochemical processes. A further under-
standing of these processes at the molecular level might hopefully 
lead to specific therapeutic strategies aimed to circumvent Pt resis-
tance. 
b) Proteomic Analysis of Cellular Responses to Metallodrugs 
 There is much interest in monitoring, in “real time”, the pro-
teomic responses of cells to cytotoxic metallodrugs as such re-
sponses might provide valuable information on the mechanism of 
action of the drug itself and might highlight which metabolic or 
signalling pathways of the cell are primarily affected and/or acti-
vated. If the damage is too intense and cannot be repaired, specific 
biochemical pathways will be triggered ultimately leading to cell 
apoptosis. A number of studies illustrating this kind of strategy 
have appeared in the recent literature.  
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 For instance, Yim et al. [52] examined differential protein ex-
pression in cisplatin-treated HeLa cervical carcinoma cells. In total, 
21 protein spots were found to be differentially expressed following 
cisplatin treatment, of which 12 were upregulated (e.g. regulator of 
G-protein signaling, TRAF:TNF (tumor necrosis factor) receptor-
associated factor-interacting protein [I-TRAF], and cyclin-
dependent kinase inhibitor p27 [p27(kip1)]) and 9 were downregu-
lated (eg, myc proto-oncoprotein [c-myc] and proliferating cell 
nuclear antigen). On the basis of proteomic data, these authors re-
vealed that cisplatin induced TRAF2-mediated NF-kappaB down-
regulation; in addition, they demonstrated that cisplatin triggered 
both membrane death receptor-mediated and mitochondria-
mediated apoptosis pathways.  
 In turn, Yao et al. [53] carried out comparative proteomic stud-
ies of colon cancer cells in response to oxaliplatin treatment. Two-
dimensional gel electrophoresis coupled with MALDI-TOF/TOF 
mass spectrometry revealed 57, 48, and 53 differentially expressed 
proteins in three distinct cell lines (HT29, SW620 and LoVo, re-
spectively) after Oxaliplatin treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Venn diagram of differentially expressed protein that overlapped 
between the cell lines, as identified by MALDI_TOF/TOF analysis. The 
identified proteins are indicated by their HUGO gene name (from ref. 53). 
 Of these proteins, 21 overlapped among all three cell lines. 
These overlapping proteins participate in many cellular processes, 
such as apoptosis, signal transduction, transcription and translation, 
cell structural organization, and metabolism. Additionally, the ex-
pression levels of ezrin (EZRI), heat-shock protein beta-1 (HSPB1), 
translationally controlled tumor protein (TCTP), and cell division 
control protein 2 homolog (CDC2) were confirmed by immunoblot-
ting. Several interesting proteins that were identified in this study 
warrant further investigation owing to their potential role in the 
antitumor effect of Oxaliplatin. 
 Remarkably, a few detailed studies concerning proteomic 
analysis of cellular response to treatment with gold-based metallo-
drugs were reported by the group of Prof. Chi Ming Che, Hong 
Kong. [54] A 2DE-based proteomic technology was used by these 
authors to investigate protein expression profiles in human naso-
pharyngeal carcinoma SUNE1 cells treated with gold (III) porphy-
rin 1a. [38]. Relevant changes in the expression of a few proteins 
involved in redox metabolism, in the mitochondrial functions and in 
apoptosis were highlighted. In particular, the voltage-dependent 
anion channel 1 (VDAC 1) was found to be greatly upregulated in 
consistency with previous observations. VDAC1 is a mitochondrial 
outer membrane channel protein that constitutes main pathway for 
the transfer of various substances in and out of the mitochondria 
[55]. It is considered to be part of the permeability transition pore 
oligoprotein complex. Such large alterations of VDAC expression 
point out that mitochondria could be a primary target for gold(III) 
porphyrin 1a. Overall, the above mentioned papers documented the 
feasibility and the effectiveness of this kind of strategy. However, 
several aspects of the mechanism of gold(III) porphyrins still re-
main to be clarified.  
 Very recently, we have exploited a classical proteomic ap-
proach to gain a deeper insight into the mechanism of two cytotoxic 
gold compounds, namely Auoxo6, a binuclear gold(III) complex 
showing a very favourable cytotoxic profile, and auranofin, a clini-
cally established gold(I) antiarthritic drug, causing relevant tumor 
cell growth inhibition in vitro [56]. First, the 72h cytotoxicity pro-
files of Auoxo6 and auranofin were carefully recorded against 
A2780 human ovarian carcinoma cells, either sensitive or resistant 
to cisplatin. Subsequently, protein extraction from gold-treated 
A2780/S cells (after 24 hours drug exposure) and 2D Gel electro-
phoresis protein separation were carried out according to estab-
lished procedures and differentially expressed proteins were 
searched for. Notably, both metallodrugs turned out to induce rela-
tively modest changes in the overall protein expression pattern in 
comparison to controls as only 11 out of ?1300 monitored proteins 
revealed appreciable quantitative changes. Very remarkably, six 
altered proteins were in common between the two gold drug treat-
ments suggesting a strong similarity in their respective mode of 
action. Eight altered proteins were identified by MALDI TOF 
analysis: among them, notably, ezrin, a protein associated to the 
cytoskeleton and involved in apoptosis. Interestingly, two of the 
altered proteins, peroxiredoxins 1 and 6, play a crucial role in the 
cell redox metabolism suggesting that the intracellular redox bal-
ance is significantly perturbed by these gold drugs. Increased cleav-
age of heterogenous ribonucleoprotein H was also evidenced con-
sistent with caspase 3 activation. Thus, the results of this proteomic 
study highlight that the mode of action of Auoxo6 is strictly related 
to that of auranofin; that the induced alterations of protein expres-
sion are limited and selective; that both gold compounds trigger 
caspase 3 activation; that some of the affected proteins are primar-
ily involved in the redox homeostasis suggesting that cell damage 
probably arises from oxidative stress.  
 Some interesting results were recently communicated by Kon-
carevic et al. [57] concerning the proteomic response of glioblas-
toma cells to terpyridineplatinum(II) complexes. Terpyridineplati-
num(II) complexes (TPCs) efficiently inhibit the proliferation of 
glioblastoma cells in vitro and have been tested successfully in a 
rodent model of brain glioblastoma. Apart from intercalation with 
DNA, the major mechanism of action of TPCs seems to be a very 
potent and specific interaction with the human selenoprotein thiore-
doxin reductase (TrxR). TrxR plays a crucial role in the cellular 
redox homeostasis and protection against oxidative damage. In 
many malignant cells the thioredoxin system is upregulated, pro-
moting tumor growth and progression. Accordingly, the thioredoxin 
system has been proposed to be an attractive target for cancer ther-
apy. The study by Koncarevic et al. gives the first comprehensive 
overview of the effects of TPCs on the transcriptome and proteome 
of glioblastoma cells. Under TPC treatment, mechanisms contrast-
ing TrxR inhibition are activated in parallel to DNA-damage-
responsive pathways. TPC pressure results into long-term compen-
satory upregulation of TrxR expression. In parallel, p53 is acti-
vated, leading to a range of regulations typical for cell-cycle-
arrested cells such as upregulation of CDKN1A, induction of 
GADD45, inhibition of eIF5A maturation, and reduced phosphory-
lation of stathmin. It was also shown that TPCs induce endoplasmic 
reticulum stress, as they activate the unfolded protein response. 
Thus, this profiling study provides a thorough insight into the spec-
trum of cellular events resulting from specific TrxR inhibition and 
characterizes the TPC mode of action. 
 Overall, the studies mentioned in this paragraph highlight the 
complex cellular responses to stress caused by metallodrugs. Obvi-
ously, more data need to be gathered to carry out well grounded 
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comparisons and establish meaningful correlations between the 
nature of the metallodrugs and the type of observed proteomic re-
sponse. Moreover, there is the need to deepen the analysis of the 
proteomic data through the implementation of strong and reliable 
bioinformatic tools. Such efforts will facilitate the interpretation of 
the observed proteomic changes in term of affected biochemical 
pathways and processes.  
 However, some indications already emerge from the above 
described studies. In most cases, only a few categories of proteins 
emerged that are primarily concerned with the cell response to met-
allodrugs such as proteins of the redox metabolism and mitochon-
drial proteins. Of course, much attention must be paid now to dis-
tinguish whether the observed proteomic alterations are just a part 
of the overall cell defence response or represent early signs of the 
apoptotic process.  
5. METALLOMICS: A TENTATIVE DEFINITION 
 The term “metallome” was first introduced by R.J.P. Williams 
in 2001 [58] to define the distribution of free metal ions in every 
cellular compartment. Subsequently, the term Metallomics was 
proposed to define the “study of the metallome.” Szpunar (2005) 
[59] defined “metallomics” as the "comprehensive analysis of the 
entirety of metal and metalloid species within a cell or tissue type". 
Therefore, metallomics may be considered as a specific branch of 
metabolomics specifically devoted to the study of metal-containing 
species, even though metals are not typically considered as 
metabolites. There were other attempts to define Metallomics. Ac-
cording to Hiroki Haraguchi [60], metalloproteins, metalloenzymes 
and other metal- containing biomolecules are defined as “metal-
lomes , in a similar manner to genomes in genomics and proteomes 
in proteomics. Since the identification of metallomes and the eluci-
dation of their biological or physiological functions in the biologi-
cal systems is the main research target of metallomics, chemical 
speciation for specific identification of bioactive metallomes is one 
of the most important analytical technologies to establish metallom-
ics as the integrated bio-metal science. Thus “Metallomics” may be 
viewed as an “integrated biometal science”.  
 In his review Haraguchi also presented a classification of the 
major areas of metallomics and of the respective analytical tech-
niques. According to this interpretation, metallomics covers several 
important research areas as reported in Table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). A schematic model of a biological system, showing the relation-
ships among genomics, proteomics, metabolomics and metallomics, where 
metallic ions are shown as M (from ref. 60). 
 In turn, Shi et al. [61] CMLS provided a clear distinction be-
tween metalloproteomics and metallomics. Metalloprotoemics is 
the study of metalloproteins where metallomics is the study of all 
metal containing species.  
 The object and the methods of metallomics were defined in 
greater detail by Szpunar and Lobisnki in a comprehensive review 
appeared in 2009 [62]. 
 According to these authors, the emerging field of metallomics 
refers to the entirety of research activities aimed at the understand-
ing of the molecular mechanisms of metal-dependent life processes. 
It follows that Metallomics is a new discipline greatly concerned 
with the implementation of all analytical techniques and methods 
that are required for probing the interactions between metal ions 
and the organism's genome, proteome and metabolome. Particular 
attention has to be paid to the in vivo screening for the native metal-
protein and metal-metabolite complexes by hyphenated techniques 
that combine a high-resolution separation technique (gel electro-
phoresis, chromatography or capillary electrophoresis) with sensi-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). A: Representative 2D gel images for control cells, auranofin and auoxo 6 treated cells. B: Representative gel image of A2780 control cells. The box 
highlight a major area where significant and consistent alterations of protein expression were identified Circles and letters indicate differentially expressed 
proteins (from ref. 56). 
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tive elemental (inductively coupled plasma, ICP) or molecular 
(electrospray or MALDI) mass spectrometric detection. The contri-
bution of bioinformatics for the prediction of metal-binding se-
quences in proteins may result very important. In turn, molecular 
biology approaches may be of great help for the detection of metal-
dependent genes, proteins and metabolites. 
 As specified above, metallomics includes a great variety of 
investigative tools capable of providing information on metal dis-
tribution and speciation within organisms or cells. As this discipline 
is still in its infancy, standard investigation protocols are not well 
defined yet. Rather, a group of heterogeneous biophysical ad 
bioanalytical tools now exist, essentially centered on the metal, that 
need further refinement and require integration into standard and 
validated experimental procedures. In any case, ICP MS appears to 
constitute the election method for this new discipline as ICP MS is 
capable to monitor a multitude of diverse metals simultaneously 
and with a high sensitivity. Thus, according to Shy, the two main 
techniques of metallomics are ICP MS and ESI MS. From the for-
mer method detailed quantitative information may be derived on 
metal containing species whereas from the latter structural informa-
tion is typically achieved. Remarkably, ICP MS may be coupled to 
other biophysical or bioseparation tools. Alternatively metals in 
Metallomic studies may be monitored by XAS methods as de-
scribed by Ascone et al. [63] and by Hambley et al. [64]. Remarka-
bly, despite the lack of canonical or systematic investigation proce-
dures, a number of studies have appeared in recent years principally 
aimed at analysing metallodrugs in the biological systems accord-
ing to a metallomic point of view. Selected studies will be de-
scribed below. 
6. METALLOMIC STUDIES OF ANTICANCER METAL-
LODRUGS 
 In the course of the last 10-15 years several research papers 
have appeared dealing with anticancer metallodrugs that may be 
roughly referred to a metallomic approach i.e. the study of the dis-
tribution and the speciation of a metal within a certain biological 
system... Most of these studies were devoted to platinum anticancer 
metallodrugs while only a few other concern non platinum metallo-
drugs. Some selected studies will be considered below in greater 
detail 
a. Metallomic Studies of Platinum Drugs 
 A rather complete and exhaustive description of metallomic 
studies carried out so far on platinum based drugs has been pro-
vided in a very recent review [65]. This review highlights the major 
role of Analytical Chemistry, and in particular of ICP MS methods, 
in elucidating the interactions that are established between Pt-based 
and bio molecules. Notably, this review offers a summary of the 
main analytical techniques and of the most common sample treat-
ment procedures currently used in metallomics studies of anticancer 
platinum . Both are of paramount importance to investigate such 
complex samples in the effort of preserving the existing –
biomolecule interactions. In particular, separation and detection 
techniques must be carefully selected to achieve the intended goals. 
The use of multidimensional hyphenated techniques is usually nec-
essary for understanding Pt-based interactions in the organism. 
Typically, samples analysed in the studies of platinum drugs are 
blood, urine, cell , as well as the drugs themselves and their deriva-
tives. However, most of the works that were carried out on platinum 
drugs are based on in vitro experiments or incubations of standards, 
leading in some cases to contradictory results depending on the 
experimental conditions used. Though in vivo experiments repre-
sent a great challenge due to their intrinsic high complexity and to 
the low concentrations of the Pt-adducts in real samples, these stud-
ies must be necessarily undertaken to gain a deeper understanding 
of the real interactions concerning Platinum drugs.  
 Among the several papers appeared on the above issue there are 
a few ones that seem to us of particular interest and merit further 
discussion.  
 In a pioneering study, published in 2001, Paul Dyson and co-
workers [66] examined the cellular distribution of platinum in a 
bacterial model, following cisplatin treatment, in the attempt to 
identify possible metal targets. Accordingly, proteins from cisplatin 
treated bacterial cells were partially separated by 1D polyacryla-
mide gel electrophoresis and analysed by laser ablation inductively 
coupled plasma mass spectrometry; using peptide fingerprinting 
methods (PFM). Very remarkably, the band containing the highest 
levels of platinum was found to contain the outer membrane protein 
A, ompA, which might be involved in cisplatin uptake. Thus, this 
study already pointed out the possible way for the subsequent in-
vestigations aimed at target identification.  
 More recently, Sheldrick et al. expanded the approach origi-
nally proposed by Dyson. [67] They used multidimensional liquid 
chromatography and electrospray ionisation tandem mass spec-
trometry in combination to analyse platinated tryptic peptides from 
Escherichia coli cells treated with cisplatin at pH 7.0. Prerequisites 
for the LC/LC/MS/MS analysis of protein targets, that are nicely 
fulfilled by cisplatin, are: i) that the original protein binding sites 
have a high kinetic stability over a wide pH range(2.3 < pH < 8.5), 
Table 2. Research Subjects in Metallomics and the Main Respective Analytical Techniques Researches (from ref. 60) 
Research Subject Analytical Technique 
1. Distributions of the elements in the biological fluids, cell, organs, etc. Ultratrace analysis, all-elements analysis, one atom detection, one molecule detection. 
2. Chemical speciation of the elements in the biological samples and systems. Hyphenated methods (LC-ICP-MS, GC-ICP-MS, MALDI-MS, ES-MS) 
3. Structural analysis of metallomes (metal-binding molecules). X-ray diffraction analysis, EXAFS 
4. Elucidation of reaction mechanisms of metallomes using model complexes (bioi-
norganic chemistry). 
NMR, XPS, laser-Raman spectroscopy, DNA sequencer, amino acids sequencer, time-
resolution and spatial-resolution fluorescence detection. 
5. Identification of metalloproteins and metalloenzymes.  LC-ES-MS, LC-Maldi-MS, LC-ICP-MS 
6. Metabolisms of biological molecules and metals (metabolomes, metabolites). LC, GC, LC-MS, GC-MS, ES-MS, API-MSa, biosensors 
7. Medical diagnosis of health and disease related to trace metals on a multielement 
basis. 
ICP-AES, ICP-MS, graphite-furnace AAS, autoanalyser, spectrophotometry 
8. Design of inorganic drugs for chemotherapy. LC-MS, LC-ICP-MS, stable isotope tracers 
9. Chemical evolution of the living systems and organisms on the earth. Isotope ratio measurement (chronological techniques), DNA sequencer. 
10. Other metal-assisted function biosciences in medicine, enviromental science, food 
science, agriculture, toxicology, biogeochemistry, etc. 
In-situ analysis, immunoassay, food analysis, clinical analysis. 
a Atmospheric pressure chemical ionization mass spectrometry. 
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and ii) that the metal fragment remains coordinated to a significant 
number of b+ and y+ peptide ions under MS/MS fragmentation 
conditions. Matching the MS/MS spectra of the platinated tryptic 
peptides to sequences of proteins in the E. coli database allowed the 
identification of 31 protein targets for cisplatin. Whereas six of 
them were high-abundance enzymes and ribosomal proteins, five 
low-abundance DNA-binding proteins could be identified as spe-
cific platinum targets. These included the DNA mismatch repair 
protein mutS, the DNA helicase II (uvrD) and topoisomerase I 
(top1). Two efflux proteins (acrD, mdtA), the redox regulator thi-
oredoxin 1 (thiO) and the external filament-like type-1 fimbrial 
protein A chain (fimA1) were also characterised as specific cis-
platin-binding proteins. Kinetically favoured carboxylate (D, E) and 
hydroxy (S, T, Y) O atoms were identified as the Pt coordination 
sites in 18 proteins and methionyl S atoms in 9 proteins. Again, 
such an approach is susceptible of further extension to cisplatin 
treated human cancer cells.  
 In an interesting paper appeared in 2003, Timerbaev, Keppler et 
al. [68], using cisplatin as a reference compound, revealed that 
capillary electrophoresis (CE) may be exploited to reliably assess 
drug/HSA interactions. Since cisplatin is small compared to the size 
of the protein, the binding response could only be recognized when 
applying CE coupled to a (platinum) -specific mode of detection, 
namely inductively coupled plasma-mass spectrometry (ICP-MS). 
This coupling allowed revealing the specific affinity of cisplatin 
and of novel Pt complexes for HSA, the measurement of the kinet-
ics of binding, and the determination of the number of drug mole-
cules attached to the protein. As the cisplatin/HSA molar ratio in-
creased, the reaction rate became faster with a maximum on the 
kinetic curve appearing at about 50 h of incubation at 20 times ex-
cess of cisplatin. The reaction was characterized as a pseudo-first 
order reaction. When incubated with a 20-fold excess of cisplatin, 
HSA bound up to 10 mol of Pt per mol of the protein. This is in-
dicative for a strong metal-protein coordination occurring at several 
HSA sites other than the only protein cysteine residue. Structural 
analogs of cisplatin, bearing aminoalcohol ligands, showed compa-
rable protein binding reactivity and stoichiometry but a common 
equilibrium was not reached even after one week of incubation.. 
Overall these results demonstrated the suitability of CE-ICP-MS as 
a rapid assay for high-throughput studying of drug/protein interac-
tions. 
 Trevor Hambley and coworkers [69], in a number of papers 
now summarised in a comprehensive Chem Rev. article [70] devel-
oped some elegant strategies aimed to monitor platinum distribution 
inside cancer cells and also to perform detailed speciation studies. 
In particular XAS and fluorescence methods turned out very infor-
mative for this purpose. The use of XAS methods was specifically 
exploited to monitor reduction of Pt(IV) complexes inside the re-
ducing environment of cancer cells.  
 In turn, Dan Gibson and coworkers [71] developed an ingen-
ious method directed to discriminate between low molecular 
weight, intermediate molecular weight and high molecular weight 
ligands for cisplatin. These studies were grounded on NMR meas-
urements coupled to simple, low resolution, separation methods. It 
is known that the interactions of cisplatin with a variety of biologi-
cally occurring nucleophiles can potentially enhance the efficacy of 
the drug by mediating its delivery to nuclear DNA or inactivate the 
drug by binding it irreversibly or by labilizing the NH3 ligands. 
Despite the potential importance of trans-labilization reactions in 
the mechanism of action of cisplatin, few detailed studies on trans 
labilization of the ammines had been conducted before. Gibson et al 
used 2D NMR to show that some trans labilization occurs in prolif-
erating cells and that aqueous extracts of cancer cells were able to 
labilize ca 20% of the amine ligands of cis-[PtCl2(
13CH3NH2)2] 
after 12-h incubation. Both low molecular mass nucleophiles (less 
than 3 kDa) and high molecular mass nucleophiles (more than 3 
kDa) were found to labilize the amines with similar efficiency. 
Studies with model compounds showed that thiols and thioethers 
bind to platinum(II) at similar rates, but thioethers are significantly 
more efficient at labilizing the am(m)ine at lower pH. Quantifica-
tion of the platinum adducts obtained from incubation of cisplatin 
with cell extracts indicated that two thirds of the platinum is bound 
to cellular components with molecular mass greater than 3 kDa. In 
turn, Pt(IV) complexes must be reduced to kill cancer cells. The 
reduction of cis,trans,cis- [PtCl2(OCOCH3)2(NH3)2] by extracts of 
three cell lines was measured, and the rates follow the order 
A2780cisR > A2780 > HT-29. It emerged from these measurements 
that reduction is not carried out by the low molecular weight (MW) 
antioxidants but primarily by cellular components with MW > 
3000. These studies documented the suitability and the value of 
NMR studies coupled to simple separation procedures.  
b) Metallomics Studies of Non-Platinum Metallodrugs 
 In addition, a few metallomic papers were devoted to the 
mechanistic investigation of non-platinum metallodrugs. Some of 
them are described below in more detail. 
 In analogy with the above mentioned paper on platinum com-
pounds, Sheldrick et al. employed an automated multidimensional 
protein identification technology, (MudPIT) [72], which combines 
biphasic liquid chromatography and electrospray ionisation tandem 
mass spectrometry (MS/MS), to analyse tryptic peptides from Es-
cherichia coli treated with the antiproliferative agent [(eta(6)-p-
cymene)RuCl(2)(DMSO)]. MS/MS spectra were recorded for mo-
lecular ions generated by neutral loss of p-cymene from peptide 
ions coordinated by the (? p-cymene)Ru(II) fragment. Matching of 
the MS/MS spectra of the ruthenated peptides to spectra of proteins 
in the E. coli database allowed identification of five protein targets 
for this ruthenium arene. One of these proteins is the constitutive 
cold-shock protein cspC, which regulates the expression of genes 
encoding stress-response proteins, while three of the other targets, 
ppiD, osmY and sucC, are proteins of the latter type. The DNA 
damage-inducible helicase dinG was likewise established as a pro-
tein target. Aspartate carboxylate functions were identified as the 
probable ruthenium binding sites in cspC, ppiD and dinG, and 
threonine and lysine side chains in osmY and sucC, respectively. 
This investigation confirmed the general validity of the applied 
methodology.  
 In an interesting paper appeared in 2007 Sadler et al. [73] re-
ported on the use of a radioactive label for metallodrug distribution 
studies. More in detail, the organometallic half-sandwich RuII arene 
anticancer complex [(?6-fluorene)Ru(en)Cl]PF6 (1) was synthesized 
in high yield and purity on a micromole scale with incorporation of 
the ?-emitting radioisotope 106Ru (half-life = 1.01 y) using a refined 
procedure involving conversion of RuCl3 into [(?6-fluorene) 
RuCl2]2, and then [(?6-fluorene)Ru(CH3CN)2Cl]PF6 as intermedi-
ates. Distribution studies 0.25 h post i.v. injection of 106Ru-1 at a 
dose of 25 mg 1 kg-1 showed that 106Ru is well distributed through-
out the tissues of a rat. This was the first report of the radiolabelling 
of a potential ruthenium antitumour agent for distribution/biological 
studies. Despite the problems and the difficulties intrinsic to the use 
of radioactive isotope, radiolabeling seems still to be an attractive 
option due to selectivity and sensitivity.  
 Again, Hagen et al. [74] reported very recently on the use of 
radioisotopes for metalloproteomics studies. A combination of 
techniques was developed to separate and quantify the native pro-
teins associated with a particular transition metal ion from a cellular 
system developed. The procedure basically involves four steps: (1) 
labeling of the target proteins with a suitable short-lived radioiso-
tope (suitable isotopes are (64)Cu, (67)Cu, (187)W, (99)Mo, 
(69)Zn, (56)Mn, (65)Ni); (2) separation of intact soluble holopro-
teins using native isoelectric focusing combined with blue native 
polyacrylamide gel electrophoresis into native-native 2D gel elec-
trophoresis; (3) spot visualization and quantification using autora-
diography; and (4) protein identification with tandem mass spec-
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trometry. The method was specifically applied to the identification 
of copper proteins from a soluble protein extract of wild-type Es-
cherichia coli K12 using the radioisotope (64)Cu. The E. coli pro-
tein CueO, which has previously been only identified as a multi-
copper oxidase following homologous overexpression, was now 
directly detected as a copper protein. The retention of the radioiso-
tope by the copper proteins throughout the separation process cor-
roborates the method to be genuinely native. The procedure devel-
oped here can be applied to cells of any origin, and to any metal 
having suitable radioisotopes. This kind of methodology, although 
troublesome, might be successfully applied to metallodrugs and to 
the identification of their protein targets.  
 Finally, we like to cite an interesting review paper published by 
Hong Zhe Sun et al. in Metallomics. 2009 [75].This review beauti-
fully summarises recent developments in the identification of either 
binding or “responsive” proteins to metallodrugs and of their target 
sites for a variety of platinum-, ruthenium-, gold-, arsenic- and bis-
muth-containing agents, based on proteomics and metallopro-
teomics studies. Moreover, an interesting table is reported where a 
number of proteins that are “responsive” to metallodrugs are  
compiled (Table 3). This kind of information may offer a rationale 
for understanding metal induced biochemical damage and the cor-
responding cellular response. Moreover, in this review, particular 
attention is devoted to the detailed description of the relevant ana-
lytical methodologies.  
7. CONCLUSIONS AND PERSPECTIVES 
 The great value of proteomics in metal-based drug discovery 
and development, especially in elucidating and mapping drug action 
mechanisms, has been clearly demonstrated through many success-
ful examples from the recent literature. Proteomic methods were 
recognized as a promising and powerful investigative strategy that 
can allow the systematic characterization of cellular responses to 
metal based drugs and help identifying the respective targets and 
pathways. However, there are still some relevant limitations to this 
kind of approach. Several membrane proteins are typically lost or 
degraded in the course of the proteomic studies; in addition low 
molecular weight proteins are similarly lost. Moreover, it is also 
possible that damage caused by metallodrugs is not immediately 
evident as damaged proteins are not inducible. In addition, dis-
crimination of cell defence mechanisms from damage mechanisms 
may be not so straightforward. All these arguments imply that a 
simple proteomic approach per se may not be sufficient to provide 
conclusive mechanistic information on anticancer metallodrugs. 
 In turn, we have shown that several analytical and physico-
chemical methods, centered on the metal and recently developed 
and organised into the new field of Metallomics, are now available 
that allow identification of the metal in complex biological mixtures 
with a relatively high sensitivity. These methods permit tracking the 
uptake, the distribution, the transformation and the fate of metallo-
drugs within complex biological systems. In other words, a direct 
and continuous monitoring of the metal “in real time” is typically 
achieved.  
 Based on these considerations and on the incredible rapidity of 
technological progress, it is possible to predict the likely evolution 
of this research area. We believe that a tight coupling of proteomics 
strategies with sensitive analytical methods for metal detection 
(metallomics) will allow in the close future a straightforward and 
precise identification of metal distribution within the hundreds of 
proteins that are normally separated within 2D gels. Realistically, 
an increase in sensitivity and in spatial resolution of LA ICP MS 
methods will allow the rapid scanning of 2D gels to determine the 
quantitative distribution of the metal. This kind of strategy will 
permit a strong progress in this research area as in principle all 
proteins capable of binding tightly the metal will be identified. It is 
very likely that among these proteins are those that are the effective 
targets for the various metallodrugs: in addition proteins may be 
identified that are responsible for toxicity and for resistance. Obvi-
ously, such technological progresses must be accompanied and 
supported by a parallel progress in the interpretative tools; bioin-
formatics is the discipline specifically deputed to perform data min-
ing and translate the observed metal-dependent proteomic changes 
into specific information on the affected cellular pathways and on 
the putative biomolecular targets. In conclusion we believe that a 
further and tight integration of the two described approaches (pro-
teomics and metallomics) will turn crucial for a better understand-
ing of the underlying mechanisms and for the eventual elucidation 
of the mode of action of anticancer metallodrugs. 
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